Schisandrin B-mediated TH17 cell differentiation attenuates bowel inflammation. (April 2021)

• Record Type: Journal Article
• Authors: Ma, Zeyu; Xu, Gang; Shen, Yingying; Hu, Shufang; Lin, Xia; Zhou, Jun; Zhao, Wei; Liu, Jian; Wang, Jiaoli; Guo, Jufeng
• Is Part Of: Pharmacological research. Volume 166(2021)
• Publication Date: 2021-04
• Subjects: Sch B Schisandrin B -- TH17 cells T helper 17 cells -- IBD inflammatory bowel disease -- MS multiple sclerosis -- STAT3 signal transducer and activator of transcription 3 -- IL-6 interleukin-6 -- TGF-β1 transforming growth factor β1 -- APCs antigen presenting cells -- DSS dextran sodium sulfate -- DAI the disease activity index -- MAPK mitogen-activated protein kinase -- NF-κB the nuclear factor kappa B -- ROR-γt retinoic acid-related orphan receptor-γt -- Smad sma- and mad-related protein; Chemical compounds studies in this article Schisandrin B (PubChem CID: 108130) -- Inflammatory bowel disease -- TH17 cell -- STAT3; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2021.105459
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: The transcription factor STAT3 facilitates naïve CD4 + T cells differentiation into TH 17 cells. While, Sch B decreases IL-17A production of CD4 + T cells by targeting STAT3 in vitro and in vivo . TH 17 cells promotes the pathogenesis of IBD. Thus, Sch B alleviates IBD through decreasing TH 17 cells. Highlights: Schisandrin B alleviates DSS-induced acute and chronic colitis. Schisandrin B alleviates CD4 + CD45RB high T cell-induced colitis. Schisandrin B protects mice from colitis by targeting TH 17 cells. Schisandrin B decreases TH 17 cell differentiation in a STAT3 dependent manner. Schisandrin B inhibited human TH 17 cell differentiation in vitro . Abstract: Schisandrin B (Sch B) is the major active constituent of the traditional Chinese medicine Schisandra chinensis and has anti-inflammatory activity, but the target of Sch B remains unclear. T helper 17 (TH 17) cells have been involved in the pathogenesis of many autoimmune and inflammatory diseases. Here, we showed that Sch B could decrease IL-17A production of CD4 + T cells by targeting STAT3 in vitro . Importantly, Sch B has therapeutic effects on DSS-induced acute and chronic colitis, CD4 + CD45RB high T cell-induced colitis. Furthermore, we identified TH 17 cells as the direct target of Sch B for mediating its anti-inflammatory activity. Sch B could serve as a lead for developing new therapeutics against TH 17 cells or IL-17A cytokine-driven diseases.